TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
Analyst Ratings
This is a breakdown of recent ratings and price targets for TransMedics Group and BioLife Solutions, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
TransMedics Group | 0 | 2 | 3 | 0 | 2.60 |
BioLife Solutions | 0 | 2 | 8 | 0 | 2.80 |
TransMedics Group presently has a consensus price target of $24.00, indicating a potential downside of 30.82%. BioLife Solutions has a consensus price target of $32.4444, indicating a potential downside of 17.49%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts clearly believe BioLife Solutions is more favorable than TransMedics Group.
Earnings & Valuation
This table compares TransMedics Group and BioLife Solutions' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
TransMedics Group | $23.60 million | 39.92 | $-33,550,000.00 | ($2.36) | -14.70 |
BioLife Solutions | $27.37 million | 47.03 | $-1,660,000.00 | $0.08 | 491.50 |
BioLife Solutions has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.
Institutional & Insider Ownership
76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 22.3% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares TransMedics Group and BioLife Solutions' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
TransMedics Group | -131.35% | -38.95% | -24.10% |
BioLife Solutions | 12.67% | 0.53% | 0.43% |
Summary
BioLife Solutions beats TransMedics Group on 11 of the 14 factors compared between the two stocks.